Health authorities have allocated 70,000 Ervebo Ebola vaccine doses to the Democratic Republic of the Congo to combat the country’s largest-ever outbreak. Fifty thousand doses will protect frontline health workers, while 20,000 doses support a Phase 3 clinical trial evaluating cross-protection against the Bundibugyo ebolavirus strain.
The global health response to the worsening epidemic in the Democratic Republic of the Congo (DRC) has entered a critical new phase. Following an official request from the Congolese Ministry of Public Health, the International Coordinating Group (ICG) on Vaccine Provision approved the emergency release of 70,000 doses of the Ervebo vaccine, according to Channelafrica.
The deployment addresses a fast-growing health crisis driven by a pathogen distinct from the strain the vaccine was originally designed to combat. While Ervebo is officially licensed and recommended to prevent Ebola virus disease caused by the Zaire ebolavirus, the current outbreak in eastern DRC is fueled by the Bundibugyo virus. The outbreak stands as the second deadliest in history, accounting for 2,478 deaths among 5,229 recorded cases.
WHO and Africa CDC welcome Ebola vaccine allocation to
Allocation Breakdown and the Phase 3 Bundibugyo Trial
The newly arrived doses are divided into two distinct operational streams designed to protect vulnerable personnel while gathering vital epidemiological data. Under guidance established by the World Health Organization’s Strategic Advisory Group of Experts on Immunization (SAGE), 50,000 doses are dedicated to vaccinating frontline health workers operating within high-risk zones.
The remaining 20,000 doses will power a late-stage Phase 3 clinical trial. Health authorities aim to determine whether the vaccine offers cross-protection against the circulating Bundibugyo strain. Early laboratory research and animal model studies indicate that Ervebo may provide some level of protection against the pathogen, though human data remains entirely absent according to WHO. The trial is expected to generate essential evidence for policymakers shaping future outbreak responses.
It is not known whether Ervebo may be protective against the Bundibugyo virus in humans. Early laboratory and animal data suggest it may provide some protection,
the WHO said.
WHO delivers Ebola vaccine to DR Congo to see
Financial Backing from Gavi and the Global Stockpile Mechanism
The global vaccine alliance Gavi has stepped in with substantial financial backing to facilitate the shipment and subsequent immunization efforts. Gavi announced it will provide $7 million to fund the vaccine transport to the DRC, alongside another $6 million to assist with vaccination execution in high-risk districts and bolster future preparedness.
The emergency stockpile itself is managed by the ICG, a coordinating body established in 1997 following major meningitis outbreaks in Africa. Its core founding partners include the International Federation of Red Cross and Red Crescent Societies, Médecins Sans Frontières, UNICEF, and the WHO, with Gavi providing the financial support for the emergency reserves. Since the ICG took over management of the emergency Ebola stockpile in January 2021, more than 56,000 doses of Ervebo have been allocated for outbreaks in the DRC alone, while an additional 167,000 doses have been deployed in preventive campaigns across Guinea-Bissau, Kenya, Sierra Leone, Uganda, and the DRC.
This is already the largest outbreak in DRC’s history, and could well become the largest outbreak ever,
said Gavi CEO Sania Nishtar, MD, PhD, in an earlier news release. Given the terrible toll on communities and frontline workers, we are encouraged that the approved Ebola vaccine Ervebo—readily available through our Gavi-funded global stockpile—could help reduce severe illness and deaths.
WHO and Africa CDC welcome the allocation of Ebola
Community Engagement and Informed Consent Protocols
Both the WHO and the Africa Centres for Disease Control and Prevention (Africa CDC) have endorsed the vaccine allocation while emphasizing the necessity of local trust. Public health officials are urging a community-led strategy that places affected populations at the center of disease control operations.
Because the vaccine is unproven against the Bundibugyo virus in humans, health agencies have placed strict emphasis on transparency. Officials insist that every recipient, whether participating in the formal clinical trial or receiving the vaccine through targeted frontline distribution, must understand the associated unknowns.
It is key that the people offered the vaccine, in the trial and otherwise, receive information of the risks, potential benefits and limitations related to the use of the vaccine in an outbreak of Bundibugyo virus and are able to provide informed consent.
